диссертации / 38
.pdf96.Kayikcioglu M, Can L, Evrengul H, et al. The effect of statin therapy on ventricular late potentials in acute myocardial infarction. Int J Cardiol 2003; 90: 63-72.
97.Kimura M, Kurose I, Russell J et al. Effects of fluvastatin on leukocyte– endothelial cell adhesion in hypercholesterolemic rats. Arterioscler Thromb Vasc Biol 1997; 17:1521–6.
98.Kosmala W., Spring A., Witkowska M. Relationship between systolic and diastolic function of the left ventricle in patients with impaired relaxation of the left ventricle without symptoms of heart failure. Attempt at quantitative estimation of diastolic function in the impaired relaxation stage // Pol.Arch.Med.Wewn. 1997. Vol. 98. №11. P.414-423.
99.Kwak B., Mulhaupt F., Myit S., Mach F. Statins as a newly recognized type of immunomodulator // Nat Med. 2000, Dec; 6: 1399–1402.
100.Krum H. et al. Statins and symptomatic chronic systolic heart failure: A post–hoc analysis of 5010 patients enrolled in Val–HeFT. Int J Cardiol 2007, 119:48–53.
101.Kureishi Y. Luo Z., Shiojima I. et al. HMG–CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis m normocholesterolemic animals . Nat Med 2000:6:1004–1010.
102.Lee TM, Chou TF, Tsai CH. Effects of pravastatin on cardiomyocyte hypertrophy and ventricular vulnerability in normolipidemic rats after myocardial infarction. J Mol Cell Cardiol 2003; 35: 1449-59.
103.Liao J.K. Isoprenoids as mediator of the biological effect of statins. J Clin Invest, 2002; v. 110: 285–288.
104.Liu T., Li G.P. Statins may prevent postoperative atrial fibrillation through autonomic modulation. Am J Cardiol 2006; 97: 1266.
105.Loh P.H. et al. The effects of initiation or continuation of statin therapy on cholesterol level and all–cause mortality after the diagnosis of left ventricular systolic dysfunction Am Heart J 2007; 153:537–44.
101
106.McFarline S.I., Muniyappa R., Francisco R., Sowers J.R. Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab. 2002; 87: 1451–1458.
107.MacGowan G., Mann D.L., Kormos R.L. et al. Circulating interleukin-6 in severe congestive heart failure. Am J Cardiol 1997; 79: 112831.
108.Makikallio T. H., Huikuri H. V., Hintze U. et al. Fractal analysis and timeand frequency-domain measures of heart rate variability as predictors of mortality in patients with heart failure // Am. J. Cardiol. – 2001.
–Vol. 87. – P. 178–182.
109.Marin F, Pascual DA, Roldan V, et al. Statins and postoperative risk of atrail fibrillation following coronary artery bypass grafting. Am J Cardiol 2006; 97(1): 55-60.
110.Mason J.C. Statins and their role in vascular protection // Clin. Sci (Lond.). – 2003. – Vol. 105, № 3. – Р. 251-266.
111.Mikami T. Cardiovascular ultrasound: applications for the assessment of cardiac function // J. Rinsho Byori 2001; 49; 325-333.
112.Mitchell L.B., Powel J.L., Gillis A.M., et al. AVID investigators: are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial. JACC 2003; 42: 81-7.
113.Mozaffarian D., Nye R., Levy W.C. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol 2004; 93:1124–9.
114.Mungall M.M., Gaw A. Statin therapy in the elderly. Curr Opin Lipidol, 2004, 15:453–457.
115.Nishimura R.A., Tajik A.J. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography in the clinician’s Rosetta Stone // J. Am. Coll. Cardiol. 1997. Vol.30.N 1. P.8-18.
102
116.Nissen S.E., Nicholls S.J., Sipahi I. et al. Effect of Very HighIntensity Statin Therapy on Regression of Coronary Atherosclerosis. The ASTEROID Trial. JAMA. Mar. 13, 2006; 295.
117.Omi H., Okayama N., Shimizu M. et al. Statins inhibit high glucose-mediated neutrophil-endothelial cell adhesion through decreasing surface expression of endothelial adhesion molecules by stimulating production of endothelial nitric oxide // Microvasc. Res. – 2003. – Vol. 65, №
2.– P. 118-124.
118.Onder G., Landi F., Volpato S., Fellin R., Carbonin P., Gambassi G. et al. Serum cholesterol levels and in–hospital mortality in the elderly. Am J Med 2003;115:265–71.
119.Pan W, Pintar T, Anton J, et al. Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. Circulation 2004; 110: II45-9.
120.Pasceri V., Willerson J. Т., Yeh Е. Т. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-2168.
121.Pasceri V., Chang J., Willerson J.T., Yeh E.T. Modulation of C- reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103:2531—2534.
122.Patel AA, White M, Shah S, et al. The relationship between statin use and atrial fibrillation. Curr Med Res and Opin 2007; 5: 1177-85.
123.Pehlivanidis AN, Athyros VG, Demitrias DS, et al. Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. Atherosclerosis 2001; 157: 463-9.
124.Poredos P. Endothelial dysfunction in the pathogenesis of atherosclerosis. Clin. Appl. Thromb. Hemost. 2001; 7(4):276-80.
103
125.Portal V.L., Moriguchi E.H., Vieira J.L., Schio S., Mastalir E.T., Buffe F., Bortolini E.B., Bruch R.S., Rodrigues R. «Comparison of the effect of two HMG CoA reductase inhibitors on LDL susceptibility to oxidation» Arq Bras Cardiol. 2003; 80 (2):156–61, 150–5.
126.Prandoni P., Bilora F., Marchiori A. et al. An association between atherosclerosis and venous thrombosis. New Engl J Med 2003; 348: 1435– 1441.
127.Rauchhaus M., Dohner W., Koloczek V. et al. Systemically measured cytokines are independently predictive for increased mortality in patients with chronic heart failure. J Am Coll Cardiol 2000; 35 (Suppl. A): 1183.
128.Rauchhaus M., Clark A.L., Doehner W., Davos C., Bolger A., Sharma R., Coats A.J., Anker S.D. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003; 43:1933–40.
129.Rauchhaus M., Koloczek V., Volk H., Kemp M., Niebauer J., Francis D.P. et al. Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int J Cardiol 2000; 76:125–33.
130.Ridker Р.М. et all. C-Reactive Protein Levels and Outcomes after Statin Therapy. N Engl J Med Jan. 6, 2005; 352:20-8.
131.Ridker P.M., Morrow D.A., Rose L.M. et al. Relative Efficacy of Atorvastatin 80 mg and Pravastatin 40 mg in Achieving the Dual Goals of Low-Density Lipoprotein Cholesterol <70 mg/dl and C-Reactive Protein <2 mg/l. An Analysis of the PROVE-IT TIMI-22 Trial. J Am Coll Cardiol. May 17, 2005; 45:1644–8.
132.Rikitake Y., Kawashima S., Takeshita S. et al. Anli–oxidative properties of fluvastatin, an HMG–CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol–fed rabbits. Atherosclerosis 2001:154:87–96.
104
133.Rosolova H., Cech J., Simon J., Spinar J., Jandova R.,Widimsky sen J. et al. Short to long term mortality of patients hospitalised with heart failure in the Czech Republica report from the EuroHeart Failure Survey. Eur J Heart Fail 2005; 7:780–3.
134.Schatz I.J., Masaki K., Yano K., Chen R., Rodriguez B.L., Curb J.D. Cholesterol and all–cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet 2001; 358:351–5.
135.Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994, 344: 1383–1389.
136.Scalia R, Gooszen M E , Jones S.P et al. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotcin H-deficicnt mice. Circulation. 2001, 103: 2598-2603.
137.Sever P.S., Poulter N.R., Dahlof B. et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOTLLA). Diabetes Care 2005; 28 (5): 1151–7.
138.Shamsham F., Mitchell I. Essentials of the diagnosis of heart failure // Cover article.-Cardiovascular medicine update. - 2000. - V. 61 (5). -
Р. 13191327.
139.Siu C. W., Lau C. P., Tse H. F. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003; 92(11): 1343-5.
140.Soto J., Beller G. Clinical Benefit of Noninvasive Viability Studies of Patients with Severe Ischemic Left Ventricular Dysfunction // Clin. Cardiol.
-2001. – №24 - P. 428-434.
141.Spargias K.S., Lindsay S.J., Kawar G.I. et al. QT dispersion as a predictor of long-term mortality in patients with acute myocardial infarction and clinical evidence of heart failure//Eur. Heart J. 1999. Aug.20 (16): 11581165.
105
142.Sparrow CP, Burton CA, Hernandez M, et al. Simvastatin has antiinflammatory and antiatherosclerotic activities independent of plasma cholesterol Arterioscler. Thromb. Vasc. Biol.lowering. 2001;21:115-121.
143.Sredniawa В., Musialik Lydka А., Pasyk S.Dispersion of the QT interval in unstale angina pectoris//Pol. Arch. Med. Wewn.— 2000.— Vol. 103.— P. 41 — 45.
144.Strandberg T.E., Vanhanen H, Tikkonen M.J. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet 1999; 353: 118-9.
145.Sutton M., Sharpe N. LeftVentricular Remodeling After Myocardial nfarction. Pathophysiology and Therapy // Circulation. - 2000. -
№101 - p. 2981-2987.
146.Teasta M., Yeh M., Lee P. et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996; 28: 964-71.
147.Torre-Amione G., Kapadia S., Benedict C. et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from of SOLVD. J Am Coll Cardiol 1996; 27: 1201-6.
148.Tsiara S, Elisaf M, Mikhalaidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin 2003; 19: 540-56.
149.Vanderheyden M., Kersschot E., Paulus W. Pro-inflammatory cytokines and endothelium-dependent vasodilatation in the forearm. Eur Heart J 1998; 19: 747-52.
150.Van der Harst P., Voors A.A., van Gilst W.H., Bohm M., van Veldhuisen D.J. Statins in the treatment of chronic heart failure: A systematic review // PloS Med. — 2006. — Vol. 3, № 8, e333. — P. 1403–1413.
151.Vasan R.S., Benjamin E.J., Levy D. Congestive heart failure with normal left ventricular systolic function. Arch. Intern. Med. 1996. №156. P.146-157.
106
152.Vredevoe D.L., Woo M.A., Doering L.V., Brecht M.L., Hamilton M.A., Fonarow G.C. Skin test anergy in advanced heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1998; 82:323–8.
153.Vrotcek B, Okrajcek R, Golicnik A, et al. Atrovastatin Therapy Increases Heart Rate Variability, Decraeses QT Variablility, and shortens QTc Interval Duration in Patients With Advanced Chronic Heart Failure. J Card Fail 2005; 9: 684-90.
154.Walter D.H., Fichtischerer S., Britten M.B.Р. 2006—2012. et al. // J. Amer. Coll. Cardiol. — 2001. — V. 38.
155.Watanabe M.A. Heart Rate Turbulence: a Review // Indian Pacing Electrophysiol. J.- 2003.- Vol.3.- P.10-22.
156.Weverling–Rijnsburger A.W.E., Blauw G.J., Lagaay A.M., Knook D.L., Meinders A.E., Westendorp R.G.J. Total cholesterol and risk of mortality in the oldest old. Lancet.1997;350:1119–23.
157.Wierzbicki A.S., Poston R., Ferro A. The lipid and non-lipid effects of statins // Pharmacol. Ther. – 2003. – Vol. 99, № 1. – P. 95-112.
158.Wilhelmsen L. Heart failure in the general population of men— morbidity, risk factors and prognosis. J Intern Med 2001; 249:253–61.
159.Young-Xu Y, Jabbour S, Goldberg R, et al. Usefulness of statin drugs against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003; 92(12): 1379-83.
107